Loading patent…
AssigneeGoldgene LLC
InventorsFernando Alberto Goldbaum, Diego Andrés Laplagne, Vanesa Zylberman, Patricio Craig, Paula Mercedes Berguer, Natalia Ainciart, Carlos Alberto Fossati, Carlos Alejandro Velikovsky, Juliana Cassataro, Guillermo Giambartolomei
Estimating the term…
Isolated chimeric proteins including up to ten copies of peptides, polypeptides or protein domains inserted in the amino termini of the Brucella spp. Lumazine synthase enzyme. Isolated nucleotide sequences codifying the chimeric proteins. Vectors, plasmids and transformed cells used for expressing the proteins. Monoclonal and polyclonal antibodies induced by the chimeric proteins. Hybridomas producing the monoclonal antibodies. Vaccines and pharmaceutical compounds including the chimeric proteins, nucleotide sequences and antibodies. A method to induce an immune response in higher organisms including the administration of effective amounts of the vaccines and pharmaceutical compounds. Biosensors including the chimeric proteins. Protein conjugates formed by the chimeric proteins and a ligand bound by means of covalent and noncovalent bonds. Uses of the chimeric proteins, nucleotide sequences, vectors, plasmids, transformed cells, antibodies, hybridomas, conjugates, biosensors, vaccines and pharmaceutical compounds. The quaternary structure of the chimeric proteins.
Isolated chimeric proteins comprising a peptide, a polypeptide or a proteic domain linked to a modified lumazine synthase protein from Brucella spp, wherein either the first 8 N-terminal residues of the modified protein have been deleted or the nucleotide sequences encoding the first 8 N-termini residues of the modified protein are replaced with DNA sequences comprising restriction sites for enzymes Nsi I and Afl II, wherein the amino acid sequence of the modified protein consists of SEQ ID NO:7.
Dependencies are inferred from the claim text.